Abstract:Introduction Cardiovascular (CV) disorders are steadily increasing, making them the world’s most prevalent health issue. New research highlights the importance of insulin-like growth factor 1 (IGF-1) for maintaining CV health Methods We searched PubMed and MEDLINE for English and non-English articles with English abstracts published between 1957 (when the first report on IGF-1 identification was published) and 2022. The top search terms were: IGF-1, cardiovascular disease, IGF-1 receptors, IGF-1 and microRNAs, therapeutic interventions with IGF-1, IGF-1 and diabetes, IGF-1 and cardiovascular disease. The search retrieved original peer-reviewed articles, which were further analyzed, focusing on the role of IGF-1 in pathophysiological conditions. We specifically focused on including the most recent findings published in the past five years. Results IGF-1, an anabolic growth factor, regulates cell division, proliferation, and survival. In addition to its well-known growth-promoting and metabolic effects, there is mounting evidence that IGF-1 plays a specialized role in the complex activities that underpin CV function. IGF-1 promotes cardiac development and improves cardiac output, stroke volume, contractility, and ejection fraction. Furthermore, IGF-1 mediates many growth hormones (GH) actions. IGF-1 stimulates contractility and tissue remodeling in humans to improve heart function after myocardial infarction. IGF-1 also improves the lipid profile, lowers insulin levels, increases insulin sensitivity, and promotes glucose metabolism. These findings point to the intriguing medicinal potential of IGF-1. Human studies associate low serum levels of free or total IGF-1 with an increased risk of CV and cerebrovascular illness. Extensive human trials are being conducted to investigate the therapeutic efficacy and outcomes of IGF-1-related therapy. Discussion We anticipate the development of novel IGF-1-related therapy with minimal side effects. This review discusses recent findings on the role of IGF-1 in the cardiovascular (CVD) system, including both normal and pathological conditions. We also discuss progress in therapeutic interventions aimed at targeting the IGF axis and provide insights into the epigenetic regulation of IGF-1 mediated by microRNAs.

Insulin-Like Growth Factor-1 Therapy in Diabetes: Physiologic Basis, Clinical Benefits, and Risks

Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus.

Novel Aspects of Insulin-like Growth Factor 1/insulin Network in Chronic Inflammatory Airway Disease

The insulin-like growth factor I system: physiological and pathophysiological implication in cardiovascular diseases associated with metabolic syndrome.

Recombinant human insulin-like growth factor-I therapy for children with growth disorders

New Insights on the Cardiovascular Effects of IGF-1

The Insulin-Like Growth Factor System in Obesity, Insulin Resistance and Type 2 Diabetes Mellitus

Glucagon-like peptide-1 and its receptors and their fuctions in the treatment of type 2 diabetes mellitus

Insulin-like growth factor-1 deficiency and metabolic syndrome

Insulin-like Growth Factor I as aÈCardiac Hormone: Physiological and Pathophysiological Implications in Heart Disease

The Fascinating Interplay between Growth Hormone, Insulin-Like Growth Factor-1, and Insulin

The role of recombinant insulin-like growth factor I in the treatment of the short child

The Insulin-Like Growth Factor System and Neurological Complications in Diabetes

Revisiting the IGF-1R as a breast cancer target

Safety of long acting insulin analogues discussed from the IGF-I receptor affinity

The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders

Insulin-Like Growth Factor Axis and Risk of Type 2 Diabetes in Women

Insulin-Like Growth Factor -1 (IGF-1) and Glucose Dysregulation in Young Adult Patients with β-Thalassemia Major: Causality or Potential Link?

Insulin, insulin receptors, and cancer

[Effects of Insulin-Like Growth Factor-1 on the Myocardium in Diabetic Rats].

[Process to insulin for type 2 diabetes mellitus therapy]